A US fund of a large Asia-based healthcare-focused venture capital firm seeks to make equity investments into early-stage life science companies. The sweet spot is seed to series B and the typical check size ranges from $5 – $10 million USD. The firm focuses on US, Canada or EU based companies. The firm prefers to co-invest or syndicate with other well-known investors.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics and Medical Technology. Digital Health and purely technology companies are less of interest.

The firm is open to working with entrepreneurs with all experience levels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm in the USA focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs.  The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.

The firm will consider investments in therapeutics and medical devices, as well as healthcare IT and services. The firm will not consider companies in pre-clinical stage, and typically invests in companies that are near commercialization and commercialization stage.

The firm focuses on private companies with strong and experienced management team. The firm usually takes a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading early-stage life science accelerator and venture firm is investing in promising early-stage assets, creates a company around each asset and then directly manages the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm only invests in therapeutics-focused opportunities. For the new fund, the firm has a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities. Founded in 2017, the firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in Boston, Shanghai, as well as Palo Alto.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A major financial institution based in Western Europe managing venture capital funds totaling to several billion, is significantly focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-8 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in companies in Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health. The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics (mainly First-In-Class), including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases. The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in the country where their headquarters are located, but will consider opportunities elsewhere in Europe: for companies in this country, the firm is typically a lead or co-lead investor, but in other regions the firm prefers to be a follow-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company dedicated to research, development, and commercialization of innovative products for unmet medical needs in the areas of musculoskeletal disorders, including pain management and critical care, is vastly investing to expand their presence from its domestic roots to become a Global Specialty Pharma. To achieve above goal, the firm is looking for opportunities of early stage pipelines and/or research collaborations with global rights to expand their business worldwide.

The firm Is pursuing attractive, new in-licensing and research collaboration opportunities in the following areas of interest: in relation to in-licensing opportunities in pre-clinical stage for the global market, the firm is interested in chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, and muscle-related disorders (i.e. DMD, ALS, etc.) In relation to research collaboration opportunities for the global market, the firm is interested in drug seeds for chronic pain, inflammatory diseases (including rheumatoid arthritis), critical care, as well as platform technologies related to drug delivery, formulation, excipients, oral, transdermal, nanoparticle, controlled release, and targeting.

The firm has no specific company or management team requirements and is willing to work with all early-stage companies globally, with promising technologies. The firm will seek global rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A therapeutic accelerator looks to in-license therapeutics assets from inventors/founders, and fund the assets’ development through clinical proof-of-concept. The firm is looking for assets throughout the United States and is actively seeking new opportunities. The firm has signed a partnership with a major VC firm, who will advise on current and future investments.

The firm is currently looking for therapeutic assets in pre-clinical through early clinical stages of development. The firm is open in terms of indication and will consider both small molecules and biologics, and will also consider drug repurposing opportunities. The firm looks to in-license these assets and accelerate their development through to clinical proof-of-concept, at which point the firm looks to partner the asset with pharmaceutical firms or other investors who will complete the commercialization of the asset. The firm has signed strategic partnerships with major pharma, regarding products in cardiovascular, metabolic, neuroscience, and immunology indications.

The firm focuses on the strength of the technology when evaluating in-licensing opportunities. The company leverages a capable and connected team and advisors for the development, funding, active management, and partnering of its portfolio of therapeutic products.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.